Stock comparison
Genmab A/S
Ligand Pharmaceuticals
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
LGND
Ligand Pharmaceuticals
Market cap
$4.6B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | LGND | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 55D | GMAB |
| Benjamin Graham | 64C | 67D | LGND |
| Philip Fisher | 48D | 64C | LGND |
| Peter Lynch | 25F | 54C | LGND |
| Joel Greenblatt | 76B | 53D | GMAB |
| Charlie Munger | 68C | 57D | GMAB |
| Terry Smith | 71C | 47D | GMAB |
Side-by-side metrics
| Metric | GMAB | LGND |
|---|---|---|
| Market cap | $16.5B | $4.6B |
| P/E (TTM) | 6.2x | 27.6x |
| EV/EBIT | 12.0x | 97.7x |
| ROIC (TTM) | 43.78% | 5.61% |
| Gross margin | 93.88% | 98.61% |
| Net margin | 18.23% | 55.95% |
| Revenue CAGR 5y | -18.45% | 2.64% |
| EPS CAGR 5y | -23.48% | 16.8% |
| Debt / Equity | 0.1x | 0.5x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- EV/EBIT12.0xvs 97.7x+88%
- ROIC (TTM)43.78%vs 5.61%+87%
- Debt / Equity0.1xvs 0.5x+84%
- P/E (TTM)6.2xvs 27.6x+78%
LGND leads on
- EPS CAGR 5y16.8%vs -23.48%+172%
- Revenue CAGR 5y2.64%vs -18.45%+114%
- Net margin55.95%vs 18.23%+67%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.